Elise Zitta

Peripheral muscle dysfunction persists in the era of highly effective CFTR modulators in cystic fibrosis.

Altered muscle performance cannot be explained solely by muscle deconditioning and lower muscle size, suggesting intrinsic muscle alterations, and support the need for comprehensive assessment of peripheral muscle function and the continued prioritisation of interventions aiming to optimise muscle health.